Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 897.72 KB
Add to list
  1. Search results
  2. Residual active pharmaceutical ingred...

Residual active pharmaceutical ingredient on the primary packaging of medicines : a valuable GMP-marker

Evelien Wynendaele (UGent) , Miguel Colpaert, Nathan Debunne (UGent) , Anne Kosgei (UGent) and Bart De Spiegeleer (UGent)
(2019) TALANTA. 201. p.259-265
Author
Organization
Abstract
Medicines are meant to help people and treat their conditions and to promote general well-being of all members of the society. Unfortunately, this is being compromised by the distribution and sale of poor-quality medicines around the world, being a consequence of non-GMP manufacturing. In this study, the contamination of the outer primary packaging with active pharmaceutical ingredient (API, i.e. artemether) is investigated as a possible and objective, quantifiable marker for GMP-compliance. First, an analytical UPLC-MS method was developed and verified for artemether, with emphasis on the quantification in the lower concentration range. Second, a swabbing procedure for the outer surface of plastic bottles (powders for suspension) was developed, including a swabbing recovery of the API from the bottle surfaces. Finally, twenty antimalarial samples were investigated. All of them showed some degree of outer contamination; however, large differences in the amount of API contamination between the different samples was observed, ranging between 4 and 144 ng/cm(2). A positive correlation was found between the amount of artemether on the packaging and the number of information elements missing on the packaging or leaflet, which was used as one of the tools to evaluate the GMP status of the manufacturer.
Keywords
GMP, Antimalarial medicines, Artemether, Primary packaging contamination, Quality, CONTAMINATION, DRUGS, QUALITY

Downloads

  • Download
    (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 897.72 KB

Citation

Please use this url to cite or link to this publication:

MLA
Wynendaele, Evelien, et al. “Residual Active Pharmaceutical Ingredient on the Primary Packaging of Medicines : A Valuable GMP-Marker.” TALANTA, vol. 201, 2019, pp. 259–65.
APA
Wynendaele, E., Colpaert, M., Debunne, N., Kosgei, A., & De Spiegeleer, B. (2019). Residual active pharmaceutical ingredient on the primary packaging of medicines : a valuable GMP-marker. TALANTA, 201, 259–265.
Chicago author-date
Wynendaele, Evelien, Miguel Colpaert, Nathan Debunne, Anne Kosgei, and Bart De Spiegeleer. 2019. “Residual Active Pharmaceutical Ingredient on the Primary Packaging of Medicines : A Valuable GMP-Marker.” TALANTA 201: 259–65.
Chicago author-date (all authors)
Wynendaele, Evelien, Miguel Colpaert, Nathan Debunne, Anne Kosgei, and Bart De Spiegeleer. 2019. “Residual Active Pharmaceutical Ingredient on the Primary Packaging of Medicines : A Valuable GMP-Marker.” TALANTA 201: 259–265.
Vancouver
1.
Wynendaele E, Colpaert M, Debunne N, Kosgei A, De Spiegeleer B. Residual active pharmaceutical ingredient on the primary packaging of medicines : a valuable GMP-marker. TALANTA. 2019;201:259–65.
IEEE
[1]
E. Wynendaele, M. Colpaert, N. Debunne, A. Kosgei, and B. De Spiegeleer, “Residual active pharmaceutical ingredient on the primary packaging of medicines : a valuable GMP-marker,” TALANTA, vol. 201, pp. 259–265, 2019.
@article{8624950,
  abstract     = {{Medicines are meant to help people and treat their conditions and to promote general well-being of all members of the society. Unfortunately, this is being compromised by the distribution and sale of poor-quality medicines around the world, being a consequence of non-GMP manufacturing. In this study, the contamination of the outer primary packaging with active pharmaceutical ingredient (API, i.e. artemether) is investigated as a possible and objective, quantifiable marker for GMP-compliance. First, an analytical UPLC-MS method was developed and verified for artemether, with emphasis on the quantification in the lower concentration range. Second, a swabbing procedure for the outer surface of plastic bottles (powders for suspension) was developed, including a swabbing recovery of the API from the bottle surfaces. Finally, twenty antimalarial samples were investigated. All of them showed some degree of outer contamination; however, large differences in the amount of API contamination between the different samples was observed, ranging between 4 and 144 ng/cm(2). A positive correlation was found between the amount of artemether on the packaging and the number of information elements missing on the packaging or leaflet, which was used as one of the tools to evaluate the GMP status of the manufacturer.}},
  author       = {{Wynendaele, Evelien and Colpaert, Miguel and Debunne, Nathan and Kosgei, Anne and De Spiegeleer, Bart}},
  issn         = {{0039-9140}},
  journal      = {{TALANTA}},
  keywords     = {{GMP,Antimalarial medicines,Artemether,Primary packaging contamination,Quality,CONTAMINATION,DRUGS,QUALITY}},
  language     = {{eng}},
  pages        = {{259--265}},
  title        = {{Residual active pharmaceutical ingredient on the primary packaging of medicines : a valuable GMP-marker}},
  url          = {{http://dx.doi.org/10.1016/j.talanta.2019.04.011}},
  volume       = {{201}},
  year         = {{2019}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: